Kjetil Boye

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5053973/publications.pdf

Version: 2024-02-01

71 papers	1,975 citations	279798 23 h-index	254184 43 g-index
73 all docs	73 docs citations	73 times ranked	3467 citing authors

#	Article	IF	Citations
1	Cytogenetic and molecular analyses of 291 gastrointestinal stromal tumors: site-specific cytogenetic evolution as evidence of pathogenetic heterogeneity. Oncotarget, 2022, 13, 508-517.	1.8	5
2	Discontinuation of imatinib in patients with oligo-metastatic gastrointestinal stromal tumor who are in complete radiological remission: A prospective multicenter phase II study.. Journal of Clinical Oncology, 2022, 40, 11535-11535.	1.6	1
3	Real-world evidence on perioperative chemotherapy in localized soft tissue sarcoma of the extremities and trunk wall; a population-based study. Acta OncolÃ³gica, 2022, 61, 793-800.	1.8	1
4	Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial. Cancer Immunology, Immunotherapy, 2021, 70, 2617-2624.	4.2	45
5	Integrating Anatomical, Molecular and Clinical Risk Factors in Gastrointestinal Stromal Tumor of the Stomach. Annals of Surgical Oncology, 2021, 28, 6837-6845.	1.5	12
6	ASO Author Reflections: How to Identify Patients at Genuinely High Risk of Recurrence from Localized Gastrointestinal Stromal Tumor of the Stomach?. Annals of Surgical Oncology, 2021, 28, 6846-6847.	1.5	0
7	Chromosomal complexity as a biomarker to de-escalate adjuvant imatinib treatment in high-risk gastrointestinal stromal tumor.. Journal of Clinical Oncology, 2021, 39, 11535-11535.	1.6	0
8	Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden. Nature Communications, 2021, 12, 3230.	12.8	95
9	Retrospective world-wide registry on the efficacy of immune checkpoint inhibitors in alveolar soft part sarcoma: Updated results from sixty patients.. Journal of Clinical Oncology, 2021, 39, 11564-11564.	1.6	4
10	Metastases in locally advanced rectal cancer undergoing curatively intended treatment. European Journal of Surgical Oncology, 2021, 47, 2377-2383.	1.0	1
11	Clinical and molecular implications of NAB2-STAT6 fusion variants in solitary fibrous tumour. Pathology, 2021, 53, 713-719.	0.6	29
12	Cell-free DNA in blood as a noninvasive insight into the sarcoma genome. Molecular Aspects of Medicine, 2020, 72, 100827.	6.4	8
13	Prospects for NK Cell Therapy of Sarcoma. Cancers, 2020, 12, 3719.	3.7	12
14	Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models. Translational Oncology, 2020, 13, 100793.	3.7	4
15	Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer â€“ the MetAction study. Acta OncolÃ³gica, 2020, 59, 733-740.	1.8	8
16	Angiosarcoma of bone: a retrospective study of the European Musculoskeletal Oncology Society (EMSOS). Scientific Reports, 2020, 10, 10853.	3.3	10
17	Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases. Cancer Biology and Therapy, 2020, 21, 432-440.	3.4	20
18	A novel risk score to predict early and late recurrence in solitary fibrous tumour. Histopathology, 2020, 77, 123-132.	2.9	16

#	Article	IF	Citations
19	A comprehensive characterization of anatomical and molecular risk factors in gastric gastrointestinal stromal tumor.. Journal of Clinical Oncology, 2020, 38, e23522-e23522.	1.6	0
20	Author response to comment on: Relationship between R1 resection, tumour rupture and recurrence in resected gastrointestinal stromal tumour. British Journal of Surgery, 2019, 106, 1102-1103.	0.3	0
21	Pazopanib in relapsed osteosarcoma patients: report on 15 cases. Acta OncolÃ³gica, 2019, 58, 124-128.	1.8	50
22	ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for the first-line treatment of metastatic gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology, 2019, 37, 11023-11023.	1.6	9
23	Angiosarcoma of bone: A European Musculoskeletal Oncology Society (EMSOS) multicenter, retrospective study.. Journal of Clinical Oncology, 2019, 37, 11046-11046.	1.6	2
24	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma. JAMA Oncology, 2018, 4, e180219.	7.1	63
25	Recurrence-Free Survival After Resection of Gastric Gastrointestinal Stromal Tumors Classified According to a Strict Definition of Tumor Rupture: A Population-Based Study. Annals of Surgical Oncology, 2018, 25, 1133-1139.	1.5	40
26	Genotype and risk of tumour rupture in gastrointestinal stromal tumour. British Journal of Surgery, 2018, 105, e169-e175.	0.3	25
27	Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. Oncologist, 2018, 23, 62-70.	3.7	62
28	Added value of 18F-FDG PET-CT in staging of Ewing sarcoma in children and young adults. European Journal of Hybrid Imaging, 2018, 2, .	1.5	4
29	Report from the 4th European Bone Sarcoma Networking meeting: focus on osteosarcoma. Clinical Sarcoma Research, 2018, 8, .	2.3	3
30	Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor. Molecular Cancer Therapeutics, 2018, 17, 2473-2480.	4.1	61
31	Abstract A101: The MetAction trial: long-lasting responses to molecularly matched therapy in end-stage cancer. , 2018, , .		1
32	Denosumab in patients with giant-cell tumor of bone in Norway: results from a nationwide cohort. Acta OncolÃ³gica, 2017, 56, 479-483.	1.8	23
33	Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer. Breast Cancer Research and Treatment, 2017, 162, 127-137.	2.5	24
34	Use of liquid biopsies to monitor disease progression in a sarcoma patient: a case report. BMC Cancer, 2017, 17, 29.	2.6	21
35	Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort. Acta OncolÃ³gica, 2017, 56, 1317-1323.	1.8	15
36	Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate. ESMO Open, 2017, 2, e000158.	4.5	8

#	Article	IF	Citations
37	Estimated cumulative radiation dose received by diagnostic imaging during staging and treatment of operable Ewing sarcoma 2005â€“2012. Pediatric Radiology, 2017, 47, 82-88.	2.0	7
38	Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma: Results of a retrospective multi-institutional case series.. Journal of Clinical Oncology, 2017, 35, 11065-11065.	1.6	2
39	The MetAction project: Biomarker-directed molecularly matched therapy for end-stage cancer implemented in clinical practice.. Journal of Clinical Oncology, 2017, 35, e14033-e14033.	1.6	0
40	Abstract 5700: CircSarc: Disease monitoring by liquid biopsies in sarcomas. , 2017, , .		0
41	Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer. Diagnostic Pathology, 2016, 11, 50.	2.0	10
42	Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour. Clinical Sarcoma Research, 2016, 6, 21.	2.3	7
43	Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a populationâ€based series and a randomized phase III study on adjuvant chemotherapy. Cancer Medicine, 2016, 5, 1840-1849.	2.8	11
44	Expression and clinical significance of Wee1 in colorectal cancer. Tumor Biology, 2016, 37, 12133-12140.	1.8	14
45	F-18-FDG PET-CT in children and young adults with Ewing sarcoma diagnosed in Norway during 2005-2012: a national population-based study. Clinical Physiology and Functional Imaging, 2016, 36, 441-446.	1.2	4
46	High expression of the cysteine proteinase legumain in colorectal cancer â€“ Implications for therapeutic targeting. European Journal of Cancer, 2015, 51, 9-17.	2.8	49
47	Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial. Cancer Immunology, Immunotherapy, 2015, 64, 769-776.	4.2	3
48	Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes. Clinical and Experimental Metastasis, 2015, 32, 755-767.	3.3	9
49	Chromosome aberrations and HEY1-NCOA2 fusion gene in a mesenchymal chondrosarcoma. Oncology Reports, 2014, 32, 40-44.	2.6	43
50	Highâ€dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: Final results of the ISG/SSG II study. Pediatric Blood and Cancer, 2014, 61, 840-845.	1.5	39
51	B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome. BMC Cancer, 2014, 14, 602.	2.6	69
52	Several fusion genes identified by whole transcriptome sequencing in a spindle cell sarcoma with rearrangements of chromosome arm 12q and MDM2 amplification. International Journal of Oncology, 2014, 45, 1829-1836.	3.3	12
53	Abstract 1093: Legumain in colorectal cancer: Unorthodox localization and trafficking. , 2014, , .		1
54	Abstract 2004: S100A4 in colorectal cancer - biological function of nuclear localization. , 2014, , .		0

#	Article	IF	Citations
55	Osteopontin is a prognostic biomarker in non-small cell lung cancer. BMC Cancer, 2013, 13, 540.	2.6	45
56	Molecular modelling and simulations in cancer research. Biochimica Et Biophysica Acta: Reviews on Cancer, 2013, 1836, 1-14.	7.4	39
57	EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer. British Journal of Cancer, 2012, 107, 667-674.	6.4	20
58	Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer. BMC Cancer, 2012, 12, 333.	2.6	14
59	Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer, 2012, 12, 505.	2.6	158
60	B7â€H3 expression in colorectal cancer: Nuclear localization strongly predicts poor outcome in colon cancer. International Journal of Cancer, 2012, 131, 2528-2536.	5.1	94
61	Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients. Tumor Biology, 2012, 33, 73-83.	1.8	3
62	Abstract 5321: Tyrosine kinase activation by the metastasis promoting protein S100A4. , 2012, , .		0
63	Disseminated tumour cells as a prognostic biomarker in colorectal cancer. British Journal of Cancer, 2011, 104, 1434-1439.	6.4	47
64	Osteopontinâ€"An important downstream effector of S100A4â€mediated invasion and metastasis. International Journal of Cancer, 2011, 129, 780-790.	5.1	46
65	Signal transduction mechanisms involved in S100A4-induced activation of the transcription factor NF-ÎºB. BMC Cancer, 2010, 10, 241.	2.6	45
66	Nuclear S100A4 is a novel prognostic marker in colorectal cancer. European Journal of Cancer, 2010, 46, 2919-2925.	2.8	42
67	S100A4 and Metastasis. American Journal of Pathology, 2010, 176, 528-535.	3.8	373
68	Abstract LB-73: Nuclear S100A4 is a novel prognostic marker in colorectal cancer. , 2010, , .		0
69	Activation of NFâ€ÎºB by extracellular S100A4: Analysis of signal transduction mechanisms and identification of target genes. International Journal of Cancer, 2008, 123, 1301-1310.	5.1	78
70	Interferon-γ-Induced Suppression of S100A4 Transcription Is Mediated by the Class II Transactivator. Tumor Biology, 2007, 28, 27-35.	1.8	8
71	Performance Characteristics of Seven Neuron-Specific Enolase Assays. Tumor Biology, 2007, 28, 27-35.	1.8	1